NASDAQ:LPCN Lipocine (LPCN) Stock Price, News & Analysis → This is the best new way to score with AI (From Weiss Ratings) (Ad) Free LPCN Stock Alerts $5.62 +0.27 (+5.05%) (As of 05/15/2024 ET) Add Compare Share Share Today's Range$5.13▼$5.6850-Day Range$3.61▼$6.5152-Week Range$2.31▼$7.15Volume27,934 shsAverage Volume55,813 shsMarket Capitalization$30.07 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestSocial Media Get Lipocine alerts: Email Address Lipocine MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy3.49% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.66Based on 6 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.00) to ($0.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.0.78 out of 5 starsMedical Sector849th out of 929 stocksPharmaceutical Preparations Industry400th out of 433 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Lipocine.Read more about Lipocine's stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted3.49% of the float of Lipocine has been sold short.Short Interest Ratio / Days to CoverLipocine has a short interest ratio ("days to cover") of 2.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Lipocine has recently decreased by 34.99%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldLipocine does not currently pay a dividend.Dividend GrowthLipocine does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for LPCN. Previous Next 3.1 News and Social Media Coverage News SentimentLipocine has a news sentiment score of 0.66. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Lipocine this week, compared to 1 article on an average week.Search Interest3 people have searched for LPCN on MarketBeat in the last 30 days. This is an increase of 50% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Lipocine to their MarketBeat watchlist in the last 30 days. This is a decrease of -80% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Lipocine insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 6.12% of the stock of Lipocine is held by insiders.Percentage Held by InstitutionsOnly 9.11% of the stock of Lipocine is held by institutions.Read more about Lipocine's insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Lipocine are expected to grow in the coming year, from ($1.00) to ($0.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Lipocine is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Lipocine is -3.29, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioLipocine has a P/B Ratio of 1.25. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Lipocine's valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad InvestorPlaceElon Musk’s Next Move Will Disrupt AI ForeverA revolutionary venture that is set to get rolled out by May 16. One well-connected Silicon Valley VC has uncovered a way for anybody to claim a stake in "Elon Musk's AI 2.0" with as little as $100.Get all the information here. About Lipocine Stock (NASDAQ:LPCN)Lipocine Inc., a clinical-stage biopharmaceutical company, engages in the research and development for the delivery of drugs for the treatment of central nervous system (CNS) disorders. Its lead product candidate is TLANDO, an oral testosterone replacement therapy (TRT) comprising testosterone undecanoate. The company's pipeline candidates also include TLANDO XR a candidate for oral TRT for once daily dosing, which has completed Phase 2b clinical study; LPCN 1148, an oral prodrug of bioidentical testosterone, being developed for the treatment of cirrhosis, currently under Phase 2 clinical studies; LPCN 1154, An oral neurosteroid, being developed for the treatment of postpartum depression, currently under Phase 2 studies; LPCN 2101, a NAS candidate, for women with epilepsy; and LPCN 2203 for essential tremor. It is also involved in the development of LPCN 1144, an oral prodrug of bioidentical testosterone for the treatment of pre-cirrhotic non-alcoholic steatohepatitis, which has completed Phase 2 testing; and LPCN 1107, an oral product candidate of 17-alpha-hydroxy progesterone caproate product, currently under Phase 3 studies for the prevention of recurrent preterm birth. The company was founded in 1997 and is headquartered in Salt Lake City, Utah.Read More LPCN Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart LPCN Stock News HeadlinesMay 13 at 3:18 AM | americanbankingnews.comLipocine (NASDAQ:LPCN) Research Coverage Started at StockNews.comMay 9, 2024 | investorplace.comLPCN Stock Earnings: Lipocine Beats EPS for Q1 2024May 9, 2024 | finance.yahoo.comLipocine Announces Financial Results for the First Quarter Ended March 31, 2024May 8, 2024 | prnewswire.comLipocine Announces Late Breaking Oral Presentation of Data from the Phase 2 Study of LPCN 1148 at EASL Congress 2024May 1, 2024 | prnewswire.comLipocine Announces Completion of Dosing in Pivotal Study of Postpartum Depression Candidate, LPCN 1154April 12, 2024 | msn.comLipocine hopes obesity drug could boost muscle mass in combo with GLP1-RAsApril 11, 2024 | finanznachrichten.deLipocine Inc.: Lipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityApril 11, 2024 | fr.investing.comLipocine annonce les résultats positifs d'une étude sur le traitement de l'obésitéApril 11, 2024 | markets.businessinsider.comLipocine Reports Positive Phase 2 Results For LPCN 2401 In Participants With ObesityApril 11, 2024 | finance.yahoo.comLipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityApril 11, 2024 | prnewswire.comLipocine Announces Positive LPCN 2401 Clinical Results Showing Improved Body Composition in Participants with ObesityMarch 28, 2024 | finanznachrichten.deLipocine Inc.: Lipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisMarch 28, 2024 | markets.businessinsider.comLipocine: LPCN 1148 Meets Primary And Hepatic Encephalopathy Endpoints In Phase 2 StudyMarch 28, 2024 | prnewswire.comLipocine Announces Positive Week 52 Results from LPCN 1148 Phase 2 Study in Patients with CirrhosisMarch 25, 2024 | finance.yahoo.comCirrhosis Clinical Trial Pipeline Insights Featuring 45+ Companies | DelveInsightMarch 25, 2024 | prnewswire.comLipocine Announces First Cohort Dosed in Pivotal Study of LPCN 1154March 7, 2024 | investorplace.comLPCN Stock Earnings: Lipocine Beats EPS for Q4 2023March 7, 2024 | seekingalpha.comLipocine GAAP EPS of -$3.14March 7, 2024 | prnewswire.comLipocine Announces Financial Results for the Full Year Ended December 31, 2023March 6, 2024 | finance.yahoo.comLipocine to Present at 36th Annual Roth ConferenceFebruary 6, 2024 | finance.yahoo.comLipocine Announces Confirmation of Dosing Regimen for Pivotal Study of LPCN 1154February 2, 2024 | finanznachrichten.deLipocine Inc.: Lipocine Announces Continued Commercialization of TLANDO through Verity PharmaceuticalsFebruary 2, 2024 | fr.investing.comLipocine transfère la commercialisation de TLANDO à Verity PharmaFebruary 2, 2024 | finance.yahoo.comLipocine Announces Continued Commercialization of TLANDO® through Verity PharmaceuticalsJanuary 18, 2024 | marketwatch.comLipocine Shares Rise Premarket on Tlando Licensing DealSee More Headlines Receive LPCN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Lipocine and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/09/2024Today5/15/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:LPCN CUSIPN/A CIK1535955 Webwww.lipocine.com Phone(801) 994-7383Fax801-994-7388Employees17Year Founded1997Profitability EPS (Most Recent Fiscal Year)($1.71) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-16,350,000.00 Net MarginsN/A Pretax Margin-190.34% Return on Equity-37.62% Return on Assets-34.60% Debt Debt-to-Equity RatioN/A Current Ratio16.99 Quick Ratio16.99 Sales & Book Value Annual Sales$500,000.00 Price / Sales60.13 Cash FlowN/A Price / Cash FlowN/A Book Value$4.48 per share Price / Book1.25Miscellaneous Outstanding Shares5,350,000Free Float5,021,000Market Cap$30.07 million OptionableNo Data Beta1.11 Social Links 10 Best Stocks to Own in 2024Click the link below and we'll send you MarketBeat's list of the 10 best stocks to own in 2024 and why they should be in your portfolio. Get This Free Report Key ExecutivesDr. Mahesh V. Patel Ph.D. (Age 67)Co-Founder, Interim Principal Financial Officer, Director, President & CEO Comp: $598.91kMs. Krista Fogarty (Age 56)Principal Accounting Officer & Corporate Controller Comp: $268.12kDr. Nachiappan Chidambaram Ph.D. (Age 54)Senior Vice President of Research & Development Comp: $311.17kMr. Logan Morse (Age 54)Vice President of Sales, Marketing & Operations Comp: $413.58kMr. Morgan R. Brown CPA (Age 56)M.B.A., Corporate Secretary Comp: $472.45kKey CompetitorsDURECTNASDAQ:DRRXTheratechnologiesNASDAQ:THTXEnlivex TherapeuticsNASDAQ:ENLVNanoViricidesNYSE:NNVCJanOneNASDAQ:JANView All CompetitorsInsidersMahesh V PatelBought 8,706 shares on 5/25/2023Total: $43,791.18 ($5.03/share)View All Insider Transactions LPCN Stock Analysis - Frequently Asked Questions How have LPCN shares performed in 2024? Lipocine's stock was trading at $2.79 on January 1st, 2024. Since then, LPCN shares have increased by 101.4% and is now trading at $5.62. View the best growth stocks for 2024 here. When is Lipocine's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our LPCN earnings forecast. How were Lipocine's earnings last quarter? Lipocine Inc. (NASDAQ:LPCN) posted its quarterly earnings data on Thursday, May, 9th. The specialty pharmaceutical company reported $0.66 earnings per share for the quarter. The specialty pharmaceutical company had revenue of $7.62 million for the quarter. When did Lipocine's stock split? Shares of Lipocine reverse split on the morning of Friday, May 12th 2023. The 1-17 reverse split was announced on Friday, May 12th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Friday, May 12th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. What other stocks do shareholders of Lipocine own? Based on aggregate information from My MarketBeat watchlists, some companies that other Lipocine investors own include Synergy Pharmaceuticals (SGYP), Flexion Therapeutics (FLXN), Trevena (TRVN), Heat Biologics (HTBX), Rigel Pharmaceuticals (RIGL), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Biocept (BIOC) and Catalyst Pharmaceuticals (CPRX). How do I buy shares of Lipocine? Shares of LPCN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:LPCN) was last updated on 5/16/2024 by MarketBeat.com Staff From Our PartnersBiden to Drop BOMBSHELL June 13th?Paradigm PressAmazon's betting big on this unknown AI companyManward PressThis Wall Street stock prediction just went viralChaikin AnalyticsThe #1 Biotech Stock to Watch in 2024 is Attacking Viruses in a Unique WaySmallcaps DailyHealthcare Takes A Big Step Forward With The Help Of AIThe Bull ReportTop 5 AI Stocks to Buy for 2024Market Moving TrendsTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeTop 5 Tech Stocks to Buy for 2024Daily Market Alerts Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lipocine Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.